Listed by the USPTO as LEITH, NANCY J
Tech Center 1600 • Art Units: 1600 1632 1636 1653 1656 1681 1683
This examiner grants 75% of resolved cases
LEITH, NANCY J is assigned to Tech Center 1600 and Art Unit 1600. The profile records 834 resolved cases, a 74.7% allowance rate, and a 44.0% interview lift. The median time to allowance is 1105 days. The interview measure is a prominent feature of the record, showing a substantial reported association with allowance outcomes within a sizeable case base.
The listed companies are The Regents of the University of California, Flagship Pioneering Inc., and Editas Medicine Inc. The listed firms are FOLEY & LARDNER LLP, FISH & RICHARDSON P.C. (TC), and K&L Gates LLP - Tessera. Counsel may place significant emphasis on preparing for examiner interviews, including concise explanations of claim distinctions and proposed amendments. The allowance rate provides context for the overall prosecution environment, while the median duration should inform filing schedules and client expectations.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17533007 | EVALUATION OF CAS9 MOLECULE/GUIDE RNA MOLECULE COMPLEXES | Non-Final OA | EDITAS MEDICINE, INC. |
| 17742127 | NOVEL CRISPR ENZYMES AND SYSTEMS | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18171578 | METHODS AND COMPOSITIONS FOR GENERATING A DELETION LIBRARY AND FOR IDENTIFYING A DEFECTIVE INTERFERING PARTICLE (DIP) | Non-Final OA | The Regents of the University of California |
| 17763110 | NOVEL RECEPTORS HAVING A HETEROLOGOUS STOP TRANSFER SEQUENCE FOR LIGAND-DEPENDENT TRANSCRIPTIONAL REGULATION | Non-Final OA | The Regents of the University of California |
| 19272711 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 19272775 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 17608429 | MULTIPARTITE CRISPR DONOR | Non-Final OA | DSM IP Assets B.V. |
| 17201347 | DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF THE CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR TARGETING DISORDERS AND DISEASES USING VIRAL COMPONENTS | Non-Final OA | President and Fellows of Harvard College |
| 17309426 | METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND USE THEREOF | Non-Final OA | Board of Regents, The University of Texas System |
| 19174171 | ENGINEERED CIRCULARIZED pegRNAs AND USES THEREOF | Final Rejection | Trustees of Boston University |
| 17832457 | METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION | Final Rejection | Temple University-of The Commonwealth System of Higher Education |
| 17503928 | CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | Non-Final OA | The Rockefeller University |
| 18107108 | COMPOSITIONS AND METHODS OF USE OF CRISPR-CAS SYSTEMS IN NUCLEOTIDE REPEAT DISORDERS | Non-Final OA | University of Iowa Research Foundation |
| 18269046 | MDH GENE-BASED POLYNUCLEOTIDE HAVING PROMOTER ACTIVITY AND USE THEREOF | Non-Final OA | TIANJIN INSTITUTE OF INDUSTRIAL BIOTECHNOLOGY, CHINESE ACADEMY OF SCIENCES |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy74.7% of resolved applications examined by Nancy J Leith were allowed (834 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +44.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Nancy J Leith took 1,105 days on average from filing to allowance.
Nancy J Leith examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
